Abstract
Background: Intravenous (IV) amiodarone is regularly administered at the current clinic unit for atrial fibrillation, including cardiology and post-cardiac surgery patients. The unit noted an increase in chemical phlebitis from the submission of reportable events. From this increase, a systematic review of administration was performed. Method: A literature review was performed of global administration guidelines – from the National Health Service, Australia, Canada and United States of America – and compared with current administration. The concentrations were similar but it was noted that IV giving sets were not filtered at the current centre. In partnership with IV therapy, correct filter IV giving sets were replaced. A retrospective review was then performed of patients, from the previous 3 months, who had received amiodarone via old IV giving sets and 3-month review was performed of new IV giving sets; chemical phlebitis rates were compared. Results: Aligning administration with international standards saw a reduction in phlebitis by 30%. There were no effects on cardioversion numbers due to increased filtration of drugs and no increased cost to the District Health Board for change of giving sets. Conclusion: Aligning administration guidelines with international standards enabled a significant reduction in rates of phlebitis. This reduced pain and infection risks for patients and reduced length of stay; thus, reducing the cost of treatment.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call